StocksFundsScreenerSectorsWatchlists
ABBV

ABBV - AbbVie Inc Stock Price, Fair Value and News

162.69USD+0.99 (+0.61%)Market Closed

Market Summary

ABBV
USD162.69+0.99
Market Closed
0.61%

ABBV Alerts

  • 2 major insider sales recently.

ABBV Stock Price

View Fullscreen

ABBV RSI Chart

ABBV Valuation

Market Cap

285.6B

Price/Earnings (Trailing)

58.74

Price/Sales (Trailing)

5.26

EV/EBITDA

34.32

Price/Free Cashflow

12.95

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

11.51%

Return on Equity

46.94%

Return on Assets

3.61%

Free Cashflow Yield

7.72%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

54.3B

Rev. Growth (Yr)

-5.42%

Rev. Growth (Qtr)

2.69%

ABBV Earnings

Earnings (TTM)

4.9B

Earnings Growth (Yr)

-66.76%

Earnings Growth (Qtr)

-53.77%

Breaking Down ABBV Revenue

52 Week Range

130.96166.20
(Low)(High)

Last 7 days

-4.8%

Last 30 days

-9.1%

Last 90 days

0.1%

Trailing 12 Months

0.1%

How does ABBV drawdown profile look like?

ABBV Financial Health

Current Ratio

0.87

Debt/Equity

5.04

Debt/Cashflow

0.44

ABBV Investor Care

Dividend Yield

1.5%

Dividend/Share (TTM)

2.63

Buy Backs (1Y)

0.17%

Diluted EPS (TTM)

2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202356.7B56.0B55.1B54.3B
202256.7B57.3B57.8B58.1B
202150.2B53.7B55.2B56.2B
202034.1B36.2B40.6B45.8B
201932.6B32.6B32.9B33.3B
201829.6B30.9B32.2B32.8B
201726.2B26.7B27.3B28.2B
201623.8B24.8B25.2B25.6B
201520.4B21.0B21.9B22.9B
201419.0B19.3B19.6B20.0B
201318.5B18.7B18.9B18.8B
201217.7B17.9B18.1B18.4B
201100017.4B
201000015.6B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of AbbVie Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 20, 2024
donoghoe nicholas
sold
-3,716,760
176
-21,082
evp, chief bus/strat officer
Mar 18, 2024
stewart jeffrey ryan
acquired
1,602,110
61.36
26,110
evp, chief commercial officer
Mar 18, 2024
stewart jeffrey ryan
sold
-10,539,500
178
-58,949
evp, chief commercial officer
Mar 01, 2024
richmond timothy j.
acquired
2,804,150
61.36
45,700
evp, chief hr officer
Mar 01, 2024
richmond timothy j.
sold
-13,415,500
177
-75,680
evp, chief hr officer
Feb 29, 2024
buckbee kevin k
sold
-908,688
176
-5,144
svp, controller
Feb 29, 2024
siatis perry c
sold
-1,754,550
177
-9,891
evp, gc and secretary
Feb 29, 2024
michael robert a.
acquired
1,257,010
58.303
21,560
pres & chief operating officer
Feb 29, 2024
michael robert a.
sold
-12,154,000
176
-68,879
pres & chief operating officer
Feb 28, 2024
gonzalez richard a
sold (taxes)
-19,733,500
178
-110,249
chairman of the board and ceo

1–10 of 50

Which funds bought or sold ABBV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
New England Professional Planning Group Inc.
new
-
228,353
228,353
0.12%
Apr 12, 2024
Northwest Quadrant Wealth Management, LLC
added
0.66
51,862
335,146
0.08%
Apr 12, 2024
NORTHWEST INVESTMENT COUNSELORS, LLC
new
-
187,773
187,773
0.05%
Apr 12, 2024
Beech Hill Advisors, Inc.
added
0.12
803,241
5,355,050
2.22%
Apr 12, 2024
Quad-Cities Investment Group, LLC
reduced
-1.16
77,035
747,179
0.44%
Apr 12, 2024
Lion Street Advisors, LLC
unchanged
-
-
918,901
0.38%
Apr 12, 2024
Perkins Coie Trust Co
reduced
-3.4
512,470
4,304,030
1.01%
Apr 12, 2024
Cohen Klingenstein LLC
unchanged
-
1,370,060
9,196,050
0.34%
Apr 12, 2024
Dynamic Advisor Solutions LLC
reduced
-3.42
920,871
11,797,300
0.40%
Apr 12, 2024
BONNESS ENTERPRISES INC
unchanged
-
1,001,100
6,719,490
2.42%

1–10 of 46

Are Funds Buying or Selling ABBV?

Are funds buying ABBV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABBV
No. of Funds

Unveiling AbbVie Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.08%
160,380,057
SC 13G/A
Jan 25, 2024
blackrock inc.
8.1%
143,180,060
SC 13G/A
Feb 16, 2023
blackrock inc.
7.8%
138,702,758
SC 13G/A
Feb 09, 2023
vanguard group inc
8.95%
158,317,552
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
146,312,069
SC 13G/A
Feb 03, 2022
blackrock inc.
7.3%
128,197,555
SC 13G/A
Feb 16, 2021
capital research global investors
2.1%
37,921,062
SC 13G/A
Feb 10, 2021
vanguard group inc
8.08%
142,563,074
SC 13G/A
Jan 29, 2021
blackrock inc.
7.0%
124,423,484
SC 13G/A
Feb 14, 2020
capital research global investors
5.8%
86,602,693
SC 13G/A

Recent SEC filings of AbbVie Inc

View All Filings
Date Filed Form Type Document
Apr 03, 2024
8-K
Current Report
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
PX14A6G
PX14A6G
Mar 26, 2024
PX14A6G
PX14A6G
Mar 22, 2024
4
Insider Trading
Mar 21, 2024
144/A
144/A
Mar 20, 2024
144
Notice of Insider Sale Intent
Mar 20, 2024
4
Insider Trading

Peers (Alternatives to AbbVie Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
355.4B
85.2B
-6.73% -11.03%
10.11
4.17
6.46% 95.94%
319.5B
60.1B
3.80% 9.39%
875.25
5.31
1.40% -97.49%
146.3B
46.5B
-7.30% -37.12%
-105.33
3.14
42.59% -114.62%
142.3B
28.2B
-1.26% 6.20%
21.18
5.05
7.09% 2.52%
84.4B
27.1B
-8.06% -18.37%
14.9
3.11
-0.60% 23.36%
14.8B
15.8B
-1.49% 59.59%
-25.72
0.93
6.17% 76.47%
MID-CAP
4.1B
4.7B
-0.79% -17.32%
-321.5
0.88
4.58% 90.97%
4.0B
1.7B
-16.49% -18.19%
11.28
2.41
49.61% 324.78%
3.2B
8.8B
-6.09% 15.35%
-5.33
0.36
7.79% -163.11%
2.0B
644.4M
-5.18% -3.16%
14.27
3.05
29.14% 50.51%
SMALL-CAP
1.4B
743.2M
4.05% -24.05%
-3.96
1.87
24.65% 80.36%
22.7M
70.0M
-17.92% -45.58%
-2.21
0.38
-19.54% -109.18%
17.5M
-
-10.43% 48.74%
-0.95
0.22
2882.68% -138.52%
1.1M
19.6M
-33.33% -94.84%
-0.07
0.05
80.00% 43.08%
546.5K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

AbbVie Inc News

Latest updates
Seeking Alpha3 hours ago
Yahoo Finance12 Apr 202408:19 pm
Yahoo Finance08 Apr 202409:50 pm

AbbVie Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue2.7%14,30113,92713,86512,22515,12114,81214,58313,53814,88614,34213,95913,01013,85812,90210,4258,6198,7048,4798,2557,8288,305
Costs and Expenses-4.6%11,10611,6469,3529,4579,61910,20911,2888,8219,81210,0369,5188,90710,1059,6479,6735,0164,7485,8624,8554,81810,746
  S&GA Expenses-5.3%3,1933,3723,2683,0393,4173,3045,4123,1273,2603,0833,1642,8423,2312,8463,5271,6951,9511,6571,6541,6801,929
EBITDA Margin-0.17*-0.25*0.22*0.29*0.32*0.31*0.31*0.29*0.19*0.18*0.15*0.15*--------
Income Taxes125.6%388172583234493448255436226508394312-1,54518746.0088.0027311766.0088.00-547
Earnings Before Taxes-37.9%1,2121,9532,6104752,9654,4001,1834,9294,2713,6881,1633,867-1,5072,500-6933,0983,0742,0018072,544-2,373
EBT Margin-20.7%0.12*0.15*0.19*0.16*0.23*0.26*0.25*0.25*0.23*0.13*0.11*0.08*---------
Net Income-53.8%8221,7782,0242392,4733,9499244,4904,0443,1797663,55336.002,308-7383,0102,8011,8847412,456-1,826
Net Income Margin-24.2%0.09*0.12*0.16*0.13*0.20*0.23*0.22*0.22*0.21*0.14*0.12*0.10*---------
Free Cashflow-38.2%4,5487,3556,1414,0187,2157,4254,8624,7464,8887,7184,6954,689---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-1.1%134,711136,221135,367134,544138,805141,325143,186143,211146,529148,858147,972150,501150,565149,621149,53091,19989,11559,44157,14256,76959,352
  Current Assets-0.7%33,00233,22428,85226,48828,46330,36429,10026,50927,92828,95725,99926,56924,17323,00921,25651,75849,51920,16615,10014,41316,945
    Cash Equivalents-3.6%12,81413,2878,7596,7119,20111,8328,5216,0989,74612,1828,5469,7558,4497,8906,01741,14239,92410,6485,1724,8977,289
  Inventory3.0%4,0993,9814,0553,8333,5793,1723,3963,4833,1283,0943,3863,2723,3103,4744,0591,8441,8131,9291,8951,7021,605
  Net PPE1.1%4,9894,9344,9434,9314,9354,8934,9585,0755,1105,1305,1615,1935,2484,9864,9082,9612,9622,8942,8792,8602,883
  Goodwill0.6%32,29332,09132,22432,22032,15631,72632,02832,29832,37932,29632,39832,34933,12442,80142,66915,56115,60415,53715,64215,60615,663
  Current Liabilities8.8%37,84134,77332,23927,59029,53832,71234,47332,52135,19428,53328,68431,95128,66124,18124,64616,47115,58517,49316,94113,90417,239
  Short Term Borrowings-100.0%-2.00-1.001.0010.0017.0012.0014.0016.0017.009.0034.0054.0064.006.00--3064993,699
  Long Term Debt-6.2%52,19455,63155,81259,29259,13560,39961,00263,52264,18974,04974,23774,18377,55482,28282,06163,28462,97533,12631,61935,06635,002
Shareholder's Equity-14.3%10,36012,09412,89813,30317,25416,02714,68816,31415,43613,57712,59413,73313,09715,28914,732------
  Retained Earnings-207.2%-1,0009331,7892,3934,7844,9533,5165,1033,1271,6007402,2921,0553,3353,1305,9734,7173,6733,3844,2343,368
  Additional Paid-In Capital0.8%20,18020,02119,83919,61919,24519,05618,90618,73118,30518,10817,93617,71217,38417,14816,95315,40115,19315,11215,02814,94014,756
Shares Outstanding0%1,7681,7681,7681,7701,7711,7711,7701,7711,7701,7691,7691,769---------
Minority Interest5.7%37.0035.0032.0029.0033.0033.0035.0031.0028.0027.0025.0023.0021.0019.0024.00------
Float---235,630---268,253---197,246---171,597---106,362--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-37.2%4,7537,5746,3194,1937,4287,6025,0054,9085,0757,9354,8904,8774,8545,8303,0893,8153,2754,5552,4773,0173,392
  Share Based Compensation-3.8%12513017931313212610730612913515926913616223621979.0075.0087.0018970.00
Cashflow From Investing-116.8%-800-369-341-499-4481,286130-1,591-1,145-615-242-342-627-1,149-35,652-129-6151,378-140-27.00-283
Cashflow From Financing-67.2%-4,449-2,661-3,920-6,192-9,634-5,518-2,679-6,972-6,338-3,643-5,884-3,174-3,695-2,814-2,570-2,42226,602-441-2,070-5,383-3,825
  Dividend Payments0.0%2,6262,6272,6252,6612,5062,5042,5072,5262,3142,3152,3102,3222,1012,1001,7521,7631,5951,5911,5921,5881,451
  Buy Backs-25.0%3.004.0010.001,9554.004.009.001,4701316.0010.0078729620.0019.006432.004.003.006202,058

ABBV Income Statement

2023-12-31
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net revenues$ 54,318$ 58,054$ 56,197
Cost of products sold20,41517,41417,446
Selling, general and administrative12,87215,26012,349
Research and development7,6756,5106,922
Acquired IPR&D and milestones7786971,124
Other operating expense (income), net(179)56432
Total operating costs and expenses41,56139,93738,273
Operating earnings12,75718,11717,924
Interest expense, net1,6842,0442,384
Net foreign exchange loss14614851
Other expense, net4,6772,4482,500
Earnings before income tax expense6,25013,47712,989
Income tax expense1,3771,6321,440
Net earnings4,87311,84511,549
Net earnings attributable to noncontrolling interest1097
Net earnings attributable to AbbVie Inc.$ 4,863$ 11,836$ 11,542
Per share data   
Basic earnings per share (in dollars per share)$ 2.73$ 6.65$ 6.48
Diluted earnings per share (in dollars per share)$ 2.72$ 6.63$ 6.45
Weighted-average basic shares outstanding (in shares)1,7681,7711,770
Weighted-average diluted shares outstanding (in shares)1,7731,7781,777

ABBV Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and equivalents$ 12,814$ 9,201
Short-term investments228
Accounts receivable, net11,15511,254
Inventories4,0993,579
Prepaid expenses and other4,9324,401
Total current assets33,00228,463
Investments304241
Property and equipment, net4,9894,935
Intangible assets, net55,61067,439
Goodwill32,29332,156
Other assets8,5135,571
Total assets134,711138,805
Current liabilities  
Short-term borrowings01
Current portion of long-term debt and finance lease obligations7,1914,135
Accounts payable and accrued liabilities30,65025,402
Total current liabilities37,84129,538
Long-term debt and finance lease obligations52,19459,135
Deferred income taxes1,9522,190
Other long-term liabilities32,32730,655
Commitments and contingencies
Stockholders' equity  
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,823,046,087 shares issued as of December 31, 2023 and 1,813,770,294 as of December 31, 20221818
Common stock held in treasury, at cost, 57,105,354 shares as of December 31, 2023 and 44,589,000 as of December 31, 2022(6,533)(4,594)
Additional paid-in capital20,18019,245
Retained earnings (accumulated deficit)(1,000)4,784
Accumulated other comprehensive loss(2,305)(2,199)
Total stockholders' equity10,36017,254
Noncontrolling interest3733
Total equity10,39717,287
Total liabilities and equity$ 134,711$ 138,805
ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
 CEO
 WEBSITEabbvie.com
 INDUSTRYPharmaceuticals
 EMPLOYEES50000

AbbVie Inc Frequently Asked Questions


What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Mon Apr 15 2024, market cap of AbbVie Inc is 285.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart for subscribers. The fair value of AbbVie Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbbVie Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABBV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, ABBV's PE ratio (Price to Earnings) is 58.74 and Price to Sales (PS) ratio is 5.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.168 (multiply by 100 for percentage) rate of return.